Bundamedik Tbk PT
IDX:BMHS

Watchlist Manager
Bundamedik Tbk PT Logo
Bundamedik Tbk PT
IDX:BMHS
Watchlist
Price: 264 IDR 4.76% Market Closed
Market Cap: 2.3T IDR
Have any thoughts about
Bundamedik Tbk PT?
Write Note

Intrinsic Value

The intrinsic value of one BMHS stock under the Base Case scenario is 358.22 IDR. Compared to the current market price of 264 IDR, Bundamedik Tbk PT is Undervalued by 26%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

BMHS Intrinsic Value
358.22 IDR
Undervaluation 26%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Bundamedik Tbk PT

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for BMHS cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about BMHS?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Bundamedik Tbk PT

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Bundamedik Tbk PT

Provide an overview of the primary business activities
of Bundamedik Tbk PT.

What unique competitive advantages
does Bundamedik Tbk PT hold over its rivals?

What risks and challenges
does Bundamedik Tbk PT face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Bundamedik Tbk PT.

Provide P/S
for Bundamedik Tbk PT.

Provide P/E
for Bundamedik Tbk PT.

Provide P/OCF
for Bundamedik Tbk PT.

Provide P/FCFE
for Bundamedik Tbk PT.

Provide P/B
for Bundamedik Tbk PT.

Provide EV/S
for Bundamedik Tbk PT.

Provide EV/GP
for Bundamedik Tbk PT.

Provide EV/EBITDA
for Bundamedik Tbk PT.

Provide EV/EBIT
for Bundamedik Tbk PT.

Provide EV/OCF
for Bundamedik Tbk PT.

Provide EV/FCFF
for Bundamedik Tbk PT.

Provide EV/IC
for Bundamedik Tbk PT.

Show me price targets
for Bundamedik Tbk PT made by professional analysts.

What are the Revenue projections
for Bundamedik Tbk PT?

How accurate were the past Revenue estimates
for Bundamedik Tbk PT?

What are the Net Income projections
for Bundamedik Tbk PT?

How accurate were the past Net Income estimates
for Bundamedik Tbk PT?

What are the EPS projections
for Bundamedik Tbk PT?

How accurate were the past EPS estimates
for Bundamedik Tbk PT?

What are the EBIT projections
for Bundamedik Tbk PT?

How accurate were the past EBIT estimates
for Bundamedik Tbk PT?

Compare the revenue forecasts
for Bundamedik Tbk PT with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Bundamedik Tbk PT and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Bundamedik Tbk PT against its competitors.

Analyze the profit margins
(gross, operating, and net) of Bundamedik Tbk PT compared to its peers.

Compare the P/E ratios
of Bundamedik Tbk PT against its peers.

Discuss the investment returns and shareholder value creation
comparing Bundamedik Tbk PT with its peers.

Analyze the financial leverage
of Bundamedik Tbk PT compared to its main competitors.

Show all profitability ratios
for Bundamedik Tbk PT.

Provide ROE
for Bundamedik Tbk PT.

Provide ROA
for Bundamedik Tbk PT.

Provide ROIC
for Bundamedik Tbk PT.

Provide ROCE
for Bundamedik Tbk PT.

Provide Gross Margin
for Bundamedik Tbk PT.

Provide Operating Margin
for Bundamedik Tbk PT.

Provide Net Margin
for Bundamedik Tbk PT.

Provide FCF Margin
for Bundamedik Tbk PT.

Show all solvency ratios
for Bundamedik Tbk PT.

Provide D/E Ratio
for Bundamedik Tbk PT.

Provide D/A Ratio
for Bundamedik Tbk PT.

Provide Interest Coverage Ratio
for Bundamedik Tbk PT.

Provide Altman Z-Score Ratio
for Bundamedik Tbk PT.

Provide Quick Ratio
for Bundamedik Tbk PT.

Provide Current Ratio
for Bundamedik Tbk PT.

Provide Cash Ratio
for Bundamedik Tbk PT.

What is the historical Revenue growth
over the last 5 years for Bundamedik Tbk PT?

What is the historical Net Income growth
over the last 5 years for Bundamedik Tbk PT?

What is the current Free Cash Flow
of Bundamedik Tbk PT?

Discuss the annual earnings per share (EPS)
trend over the past five years for Bundamedik Tbk PT.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Bundamedik Tbk PT

Current Assets 1.4T
Cash & Short-Term Investments 1.2T
Receivables 149.8B
Other Current Assets 119.6B
Non-Current Assets 2.3T
Long-Term Investments 83.2B
PP&E 2.1T
Intangibles 94.8B
Other Non-Current Assets 92.8B
Current Liabilities 808.5B
Accounts Payable 45.4B
Accrued Liabilities 27.5B
Short-Term Debt 701.4B
Other Current Liabilities 34.1B
Non-Current Liabilities 1.4T
Long-Term Debt 784.1B
Other Non-Current Liabilities 584.6B
Efficiency

Earnings Waterfall
Bundamedik Tbk PT

Revenue
1.5T IDR
Cost of Revenue
-817.5B IDR
Gross Profit
728.8B IDR
Operating Expenses
-624.9B IDR
Operating Income
104B IDR
Other Expenses
-90.9B IDR
Net Income
13B IDR

Free Cash Flow Analysis
Bundamedik Tbk PT

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

BMHS Profitability Score
Profitability Due Diligence

Bundamedik Tbk PT's profitability score is 44/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Positive Operating Income
Positive 1-Year Revenue Growth
44/100
Profitability
Score

Bundamedik Tbk PT's profitability score is 44/100. The higher the profitability score, the more profitable the company is.

BMHS Solvency Score
Solvency Due Diligence

Bundamedik Tbk PT's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Positive Net Debt
Low D/E
38/100
Solvency
Score

Bundamedik Tbk PT's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

BMHS Price Targets Summary
Bundamedik Tbk PT

Wall Street analysts forecast BMHS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BMHS is 295.8 IDR with a low forecast of 292.9 IDR and a high forecast of 304.5 IDR.

Lowest
Price Target
292.9 IDR
11% Upside
Average
Price Target
295.8 IDR
12% Upside
Highest
Price Target
304.5 IDR
15% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for BMHS?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BMHS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

Bundamedik Tbk PT Logo
Bundamedik Tbk PT

Country

Indonesia

Industry

Health Care

Market Cap

2.3T IDR

Dividend Yield

0.21%

Description

PT Bundamedik Tbk is a holding company, with engages in the provision of healthcare and medical technology services. The company is headquartered in Jakarta Pusat, Dki Jakarta and currently employs 1,285 full-time employees. The company went IPO on 2021-07-06. The firm is engaged in private hospital activities, private polyclinic activities, and other hospital activities. The Company’s also offers other hospital activities, such as healthcare services activities performed by paramedics and health support service activities. The firm operates two general clinics in Jakarta and Bekasi that offer services, such as obstetrics and gynecology specialist poly, child specialist poly, skin and aesthetic poly, dental and oral poly, general poly, medical check-ups, internal medicine poly, poly nutrition, and pharmacy. The company offers a range of services, such as mother and child services, outpatient services, inpatient services, in vitro fertilization (IVF) services, and clinical laboratory services. The firm operates approximately two maternal and child hospitals, three general hospitals, 10 IVF clinics, 14 laboratories and various other supporting business activities.

Contact

DKI JAKARTA
Jakarta Pusat
Jl. Teuku Cik Ditiro No.28, Menteng
+62215299109
bmhs.co.id

IPO

2021-07-06

Employees

1 285

Officers

President Director
Mr. Agus Heru Darjono
Director of Human Capital & Director
Ms. Emilia Rouli Simatupang
Head of Internal Audit & Risk Management Unit
Mr. Tubagus Adi Satria Prakasa
Corporate Secretary
Ms. Josephine PM Tobing

See Also

Discover More
What is the Intrinsic Value of one BMHS stock?

The intrinsic value of one BMHS stock under the Base Case scenario is 358.22 IDR.

Is BMHS stock undervalued or overvalued?

Compared to the current market price of 264 IDR, Bundamedik Tbk PT is Undervalued by 26%.

Back to Top